Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia. Subjects were randomized to treatment with standard chloroquine therapy (25 mg/kg in 3 doses over the course of 48 hours) with 30 mg primaquine administered daily for 28 days (n = 25) or a placebo of primaquine (n = 28). The 14-day cumulative incidence of therapeutic failure was 56% with primaquine and 79% with placebo (odds ratio [OR], 0.35; 95% confidence interval [CI], 0.1-1.3; P = 0.08). Primaquine administered daily created a marginally significant improvement in therapeutic efficacy at day 14, but not at day 7 (20% versus 36%; OR, 0.2; 95% CI, 0.1-1.8; P = 0.2) or day 28 (82% versus 93%; OR, 0.31; 95% Cl, 0.04-2.1; P = 0.23). This report corroborates studies suggesting that therapeutic doses of primaquine exert no discernible effect on parasitemia by P. falciparum.
Baird
J Kevin
JK
US Naval Medical Research Unit No 2, American Embassy Jakarta, Indonesia. bairdjk@namru2.med.navy.mil
Wiady
Iwa
I
Sutanihardja
Awalludin
A
Suradi
Purnomo
Basri
Hasan
H
Sekartuti
Ayomi
Ester
E
Fryauff
David J
DJ
Hoffman
Stephen L
SL
D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D015994:Incidence; D007214:Indonesia; D016778:Malaria, Falciparum / Q000188:drug therapy*; D018512:Parasitemia / Q000453:epidemiology; D010919:Placebos; D011319:Primaquine / Q000627:therapeutic use*; D012008:Recurrence
D000962:Antimalarials; D010919:Placebos; D002738:Chloroquine; D011319:Primaquine